NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of Report “Antibody Drug Conjugates: Opportunities for Technology Growth” – https://www.reportlinker.com/p06383510/ ?utm_source=GNW
Antibody drug conjugates (ADCs) are therapeutics that target cancer cells with antigen-specific antibodies and highly toxic payloads.
ADCs are currently of interest among drug developers, contract manufacturers, regulators, and other stakeholders.
The increasing number of drug approvals has also sparked interest in further development of this technology, with several companies developing solutions of one or more ADC components.
Technology development is ongoing and will only increase as the application of ADCs expands to more and more non-neoplastic indications. .
It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering various technological advances that may be employed in ADC development.
It also provides an overview of the stakeholder ecosystem and identifies notable mergers, acquisitions, and partnerships.
A detailed description of the funding situation is also provided.
The study also analyzes the growth drivers and restraints influencing the market to identify key growth opportunities resulting from changes in this sector that can be leveraged by stakeholders and market participants.
Read the full report: https://www.reportlinker.com/p06383510/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can instantly get all the market research you need in one place.